IOF Positions and Statements

The use of high-resolution peripheral quantitative computed tomography (HR-pQCT) to assess bone microarchitecture in clinical studies has continued to grow rapidly. Thus, there is an urgent need for guidance and consensus on the methods for and reporting of HR-pQCT imaging so that different studies can be compared to each other. Read more
El uso de la tomografía computarizada cuantitativa periférica de alta resolución (HR-pQCT) para evaluar la microarquitectura ósea en los estudios clínicos continúa creciendo rápidamente. Por consiguiente, existe la urgente necesidad de orientación y consenso sobre los métodos para la obtención de imágenes de la HR-pQCT y la presentación de informes a fin de poder comparar los distintos estudios... Read more
Un reconocido estudio mundial realizado en la Unidad de Epidemiología del Curso de Vida del Consejo de Investigación Médica (MRC LEU, Universidad de Southampton) en colaboración con la Fundación Internacional de Osteoporosis (IOF) y la Sociedad Internacional de Densitometría Clínica (ISCD) reporta que existe una gran variabilidad en el acceso a y en la calidad de las instalaciones de escaneo de... Read more
This article can be read in French, Japanese, Spanish, Read more
Mientras el COVID-19 continúa extendiéndose, la IOF espera que usted y su familia se mantengan seguros y saludables. Read more
A new International Osteoporosis Foundation (IOF) position paper reviews experimental and clinical evidence showing that hip bone strength estimated by bone mineral density (BMD) and/or finite element analysis (FEA) reflects the actual strength of the proximal femur. Read more
In 2018 the International Osteoporosis Foundation (IOF) and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) published the updated European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Read more
The International Osteoporosis Foundation (IOF) welcomes the decision by the Committee for Medicinal Products for Human Use (CHMP), following a re-examination procedure, to grant a marketing authorisation for romosozumab in the treatment of severe postmenopausal osteoporosis. Read more
The impact of interruption of anti-osteoporosis treatment in patients on therapy with bisphosphonates or denosumab is reviewed in a new International Osteoporosis Foundation (IOF) working group paper 'Fracture risk following intermission of osteoporosis therapy' published in the journal Osteoporosis International.* Read more
Advances in the treatment of children and adolescents with cancer have led to substantial improvements in survival, with a 5-year survival rate of childhood cancer close to 80%. Read more

Pages

Subscribe to IOF Positions and Statements